tradingkey.logo

Keros Therapeutics Inc <KROS.OQ> expected to post a loss of 24 cents a share - Earnings Preview

ReutersMay 2, 2025 2:28 PM
  • Keros Therapeutics Inc KROS.OQ KROS.O is expected to show a rise in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025

  • The Lexington Massachusetts-based company is expected to report a 2,530.5% increase in revenue to $2.183 million from $83 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Keros Therapeutics Inc is for a loss of 24 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Keros Therapeutics Inc is $26.00​, above​ its last closing price of $14.57. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.73

-0.98

-1.14

Missed

-16

Sep. 30 2024

-1.26

-1.28

-1.41

Missed

-10.2

Jun. 30 2024

-1.23

-1.23

-1.25

Missed

-1.5​

Mar. 31 2024

-1.30

-1.35

-1.21

Beat

10.2

​​Dec. 31 2023

-1.35

-1.37

-1.34

Beat

2.5

Sep. 30 2023

-1.34

-1.35

-1.33

Beat

1.3​

Jun. 30 2023

-1.33

-1.34

-1.27

Beat

5.1

Mar. 31 2023

-1.13

-1.12

-1.26

Missed

-12.2

This summary was machine generated May 2 at 14:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI